Blood markers may flag delirium risk in elderly surgery patients
NCT ID NCT07411612
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking at whether certain substances in the blood can help predict postoperative delirium—a state of confusion that can occur after surgery in older adults. Researchers will measure specific biomarkers before and after surgery in 1,170 patients aged 65 and older undergoing major non-cardiac, non-brain, and non-vascular surgery. The goal is to find a reliable way to identify those at risk early, which could improve monitoring and care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help identify patients at high risk for postoperative delirium using simple blood tests, allowing for earlier monitoring and preventive care.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any intervention, and the findings may not lead to immediate changes in patient care. The results are still uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,170 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jan 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients over the age of 65 years undergoing elective major non-cardiac, non-intrcranial, non-vascular surgery
- Ages
-
65 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Provide written informed consent * ≥ 65 years of age * Scheduled for elective major non-cardiac, non-intrcranial, non-vascular surgery with estimated time of surgery ≥ 2 hours Exclusion Criteria: * Patients undergoing emergency surgery * History of diagnosed dementia * Language, vision, or hearing impairments that may compromise cognitive assessments * Preoperative delirium * ICU patients undergoing surgery
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Blood brain barrier defect are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Medical University of Vienna
RECRUITINGVienna, 1090, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a berry extract help athletes bounce back after brutal workouts?
- Can PET scans reveal hidden heart inflammation after a stroke?
- After a stroke, does the heart inflame? MRI study probes the link
- 150,000 children to be tracked from birth to old age in massive health study
- A standard IV fluid dose may reveal who is at risk after bowel surgery
- Blood clues in depression: immune signals may flag who benefits from SSRIs